Pr Philippe Moreau
- Specialty
- Hematologist, multiple myeloma expert
- Hospital
- Centre Hospitalier Universitaire de Nantes
- Latest articles
-
- Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load. (Dec 18, 2025)
- Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. (Dec 10, 2025)
- Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent. (Nov 28, 2025)
- Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network. (Nov 25, 2025)
- Preemptive Immunoglobulin Prophylaxis Reduces Infections in Patients Treated With Anti-BCMA Bispecific Antibodies. (Oct 31, 2025)